Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Rev. méd. Chile ; 131(7): 799-807, jul. 2003.
Article in Spanish | LILACS | ID: lil-356058

ABSTRACT

BACKGROUND: All humans have the right to receive a thorough medical attention, and should not be discriminated. AIMS: To determine if there is a significant relationship between Medical Oaths that commit to the principle of no discrimination in health care and the time, origin and source of the modifications to the Hippocratic Oath. To specify which are the conditions for no discrimination. MATERIALS AND METHODS: Fifty Oaths found in different articles and publications were analyzed and selected considering their historical context. RESULTS: Of the fifty Oaths that were analyzed, nineteen express a commitment towards no discrimination, whereas one of the texts is discriminatory. The only significant relationship found was the origin and source of the texts. The most frequently discriminating factors found are social class, religion, nationality and race. At present, other factors can be found such as ideology, moral, aptitude, sex and political and sexual preferences. CONCLUSIONS: The commitment towards no discrimination is not widely found in Medical Oaths of all times (30/50). According to the bioethics principle of justice, physicians should find the limit of their obligation as doctors in providing medical assistance to everyone alike, wealthy or poor; Christians, Hebrews or Muslims; men or women; children, adults or old; with or without infectious diseases. Non discrimination should be a vow that physicians must be willing to take despite any of the factors that could influence health care.


Subject(s)
Humans , Health Services Accessibility , Hippocratic Oath , Prejudice , Quality of Health Care
2.
Rev. Fac. Med. (Caracas) ; 13(2): 104-9, jul.-dic.1990. tab
Article in Spanish | LILACS | ID: lil-100685

ABSTRACT

Ochenta y tres pacientes con artirtis reumatoidea y que recibían diclofenac sódico para el control de su enfermedad fueron seleccionados para ingresar a un estudio doble-ciego placebo controlado de 4 semanas de duración, recibiendo la mitad de ellos 50 ml de diclofenac sódico tres veces al día, y la otra mitad 50 mg de Diclofenac sódico tres veces al día más placebo. El propósito del estudio fue evaluar el efecto del misoprostol sobre las lesiones erosivas o sangrantes, dándoseles un puntaje de acuerdo a nuestro protocolo de investigación. Los pacientes que recibieron misoprostol mostraron un descenso significativo en las lesiones erosivas (112 a 31, p menor de 0.05) que al compararlas con los que recibieron placebo (123 a 60) también fué estadísticamente significativa (p menor de 0.05). No se observaron diferencias significativas en relación con las lesiones sangrantes al comparar los dos grupos. Cinco pacientes desarrollaron úlceras para el final de estudio (4 antrales y una duodenal), 4 de ellos recibieron placebo. Hubo un discreto efecto atenuante de la acción antiinflamatoria del diclonac sódico en nuestros pacientes. Se concluye que el misoprostol disminuyó significativamente las lesiones erosivas en los pacientes reumatoideos y protegió contra el efecto ulcerogénico del diclofenac sódico


Subject(s)
Adult , Middle Aged , Humans , Male , Female , Anti-Inflammatory Agents/therapeutic use , Arthritis, Rheumatoid/therapy , Diclofenac/therapeutic use , Placebos/therapeutic use , Prostaglandins, Synthetic/therapeutic use , Stomach Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL